

Myles Wolf

List of Publications by Citations

Source: <https://exaly.com/author-pdf/2934726/myles-wolf-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

244
papers

22,233
citations

68
h-index

147
g-index

270
ext. papers

25,372
ext. citations

8.5
avg, IF

6.76
L-index

#	Paper	IF	Citations
244	Vitamin D deficiency and risk of cardiovascular disease. <i>Circulation</i> , 2008 , 117, 503-11	16.7	1770
243	FGF23 induces left ventricular hypertrophy. <i>Journal of Clinical Investigation</i> , 2011 , 121, 4393-408	15.9	1351
242	Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. <i>New England Journal of Medicine</i> , 2008 , 359, 584-92	59.2	1320
241	Common genetic determinants of vitamin D insufficiency: a genome-wide association study. <i>Lancet, The</i> , 2010 , 376, 180-8	40	1183
240	Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. <i>Kidney International</i> , 2011 , 79, 1370-8	9.9	817
239	Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. <i>New England Journal of Medicine</i> , 2003 , 349, 446-56	59.2	769
238	Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. <i>JAMA - Journal of the American Medical Association</i> , 2011 , 305, 2432-9	27.4	741
237	Activated injectable vitamin D and hemodialysis survival: a historical cohort study. <i>Journal of the American Society of Nephrology: JASN</i> , 2005 , 16, 1115-25	12.7	687
236	Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2005 , 16, 2205-15	12.7	679
235	Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. <i>Circulation</i> , 2009 , 119, 2545-52	16.7	645
234	Effects of phosphate binders in moderate CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2012 , 23, 1407-15	12.7	398
233	Adiposity, cardiometabolic risk, and vitamin D status: the Framingham Heart Study. <i>Diabetes</i> , 2010 , 59, 242-8	0.9	356
232	First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 770-5	5.6	353
231	Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy. <i>Cell Metabolism</i> , 2015 , 22, 1020-32	24.6	345
230	Fibroblast growth factor-23 and cardiovascular events in CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2014 , 25, 349-60	12.7	306
229	Phosphorus binders and survival on hemodialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2009 , 20, 388-96	12.7	299
228	Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. <i>Kidney International</i> , 2016 , 89, 135-46	9.9	279

227	Update on fibroblast growth factor 23 in chronic kidney disease. <i>Kidney International</i> , 2012 , 82, 737-47	9.9	264
226	Calciophylaxis from nonuremic causes: a systematic review. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008 , 3, 1139-43	6.9	257
225	Fibroblast growth factor 23 is not associated with and does not induce arterial calcification. <i>Kidney International</i> , 2013 , 83, 1159-68	9.9	251
224	Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. <i>Journal of Bone and Mineral Research</i> , 2013 , 28, 1793-803	6.3	250
223	Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. <i>Journal of the American Society of Nephrology: JASN</i> , 2011 , 22, 956-66	12.7	222
222	Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease. <i>Kidney International</i> , 2016 , 90, 985-996	9.9	219
221	Forging forward with 10 burning questions on FGF23 in kidney disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2010 , 21, 1427-35	12.7	214
220	Fibroblast growth factor 23 and Inflammation in CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012 , 7, 1155-62	6.9	191
219	Klotho and phosphate are modulators of pathologic uremic cardiac remodeling. <i>Journal of the American Society of Nephrology: JASN</i> , 2015 , 26, 1290-302	12.7	187
218	Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010 , 95, 578-85	5.6	178
217	First-trimester C-reactive protein and subsequent gestational diabetes. <i>Diabetes Care</i> , 2003 , 26, 819-24	14.6	178
216	First trimester insulin resistance and subsequent preeclampsia: a prospective study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002 , 87, 1563-8	5.6	169
215	Preeclampsia and future cardiovascular disease: potential role of altered angiogenesis and insulin resistance. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 6239-43	5.6	165
214	Coronary Artery Calcification and Risk of Cardiovascular Disease and Death Among Patients With Chronic Kidney Disease. <i>JAMA Cardiology</i> , 2017 , 2, 635-643	16.2	154
213	Association of serum bicarbonate with risk of renal and cardiovascular outcomes in CKD: a report from the Chronic Renal Insufficiency Cohort (CRIC) study. <i>American Journal of Kidney Diseases</i> , 2013 , 62, 670-8	7.4	152
212	Impact of activated vitamin D and race on survival among hemodialysis patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2008 , 19, 1379-88	12.7	145
211	Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2011 , 26, 584-91	4.3	136
210	Patients with Fabry disease on dialysis in the United States. <i>Kidney International</i> , 2002 , 61, 249-55	9.9	134

209	Coupling fibroblast growth factor 23 production and cleavage: iron deficiency, rickets, and kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2014 , 23, 411-9	3.5	131
208	Genetic variants and associations of 25-hydroxyvitamin D concentrations with major clinical outcomes. <i>JAMA - Journal of the American Medical Association</i> , 2012 , 308, 1898-905	27.4	131
207	Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease. <i>Nature Reviews Nephrology</i> , 2014 , 10, 268-78	14.9	128
206	Fibroblast growth factor 23, cardiovascular disease risk factors, and phosphorus intake in the health professionals follow-up study. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011 , 6, 2871-8	6.9	121
205	FGF-23: More than a regulator of renal phosphate handling?. <i>Journal of Bone and Mineral Research</i> , 2010 , 25, 2091-7	6.3	120
204	Plasma FGF23 levels increase rapidly after acute kidney injury. <i>Kidney International</i> , 2013 , 84, 776-85	9.9	119
203	Postprandial mineral metabolism and secondary hyperparathyroidism in early CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2008 , 19, 615-23	12.7	118
202	Disordered FGF23 and mineral metabolism in children with CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014 , 9, 344-53	6.9	111
201	Interpreting cardiac troponin results from high-sensitivity assays in chronic kidney disease without acute coronary syndrome. <i>Clinical Chemistry</i> , 2012 , 58, 1342-51	5.5	109
200	Postpartum diabetes screening in women with a history of gestational diabetes. <i>Obstetrics and Gynecology</i> , 2005 , 106, 1297-303	4.9	108
199	Circulating levels of the antiangiogenic marker sFLT-1 are increased in first versus second pregnancies. <i>American Journal of Obstetrics and Gynecology</i> , 2005 , 193, 16-22	6.4	105
198	Effects of dietary phosphate restriction and phosphate binders on FGF23 levels in CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013 , 8, 1009-18	6.9	104
197	A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3-5. <i>American Journal of Kidney Diseases</i> , 2015 , 65, 728-36	7.4	101
196	Agonistic angiotensin II type 1 receptor autoantibodies in postpartum women with a history of preeclampsia. <i>Hypertension</i> , 2007 , 49, 612-7	8.5	98
195	Rationale and Approaches to Phosphate and Fibroblast Growth Factor 23 Reduction in CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2015 , 26, 2328-39	12.7	95
194	FGF23 at the crossroads of phosphate, iron economy and erythropoiesis. <i>Nature Reviews Nephrology</i> , 2020 , 16, 7-19	14.9	93
193	Vitamin D deficiency and anemia in early chronic kidney disease. <i>Kidney International</i> , 2010 , 77, 715-20	9.9	88
192	Longitudinal FGF23 Trajectories and Mortality in Patients with CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2018 , 29, 579-590	12.7	88

191	Serum Phosphorus and Progression of CKD and Mortality: A Meta-analysis of Cohort Studies. <i>American Journal of Kidney Diseases</i> , 2015 , 66, 258-65	7.4	86
190	Insulin resistance and alterations in angiogenesis: additive insults that may lead to preeclampsia. <i>Hypertension</i> , 2004 , 43, 988-92	8.5	84
189	Obesity and Preeclampsia. <i>Obstetrics and Gynecology</i> , 2001 , 98, 757-762	4.9	82
188	Randomized trial of intravenous iron-induced hypophosphatemia. <i>JCI Insight</i> , 2018 , 3,	9.9	80
187	First-trimester sex hormone binding globulin and subsequent gestational diabetes mellitus. <i>American Journal of Obstetrics and Gynecology</i> , 2003 , 189, 171-6	6.4	79
186	Vitamin D therapy in individuals with prehypertension or hypertension: the DAYLIGHT trial. <i>Circulation</i> , 2015 , 131, 254-62	16.7	78
185	Low socioeconomic status associates with higher serum phosphate irrespective of race. <i>Journal of the American Society of Nephrology: JASN</i> , 2010 , 21, 1953-60	12.7	76
184	A Prospective Cohort Study of Mineral Metabolism After Kidney Transplantation. <i>Transplantation</i> , 2016 , 100, 184-93	1.8	76
183	A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney disease. <i>Kidney International</i> , 2009 , 76, 705-16	9.9	75
182	High-sensitivity troponin T and N-terminal pro-B-type natriuretic peptide (NT-proBNP) and risk of incident heart failure in patients with CKD: the Chronic Renal Insufficiency Cohort (CRIC) Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2015 , 26, 946-56	12.7	74
181	Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study. <i>Nephrology Dialysis Transplantation</i> , 2012 , 27, 3270-8	4.3	74
180	Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 323, 432-443	27.4	73
179	Treatment of established left ventricular hypertrophy with fibroblast growth factor receptor blockade in an animal model of CKD. <i>Nephrology Dialysis Transplantation</i> , 2014 , 29, 2028-35	4.3	72
178	Plasma gelsolin and circulating actin correlate with hemodialysis mortality. <i>Journal of the American Society of Nephrology: JASN</i> , 2009 , 20, 1140-8	12.7	71
177	FGF23/FGFR4-mediated left ventricular hypertrophy is reversible. <i>Scientific Reports</i> , 2017 , 7, 1993	4.9	70
176	Mineral metabolites and CKD progression in African Americans. <i>Journal of the American Society of Nephrology: JASN</i> , 2013 , 24, 125-35	12.7	68
175	Inflammation and elevated levels of fibroblast growth factor 23 are independent risk factors for death in chronic kidney disease. <i>Kidney International</i> , 2017 , 91, 711-719	9.9	65
174	Effects of Nicotinamide and Lanthanum Carbonate on Serum Phosphate and Fibroblast Growth Factor-23 in CKD: The COMBINE Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2019 , 30, 1096-1108	12.7	63

173	Association of Fibroblast Growth Factor 23 With Atrial Fibrillation in Chronic Kidney Disease, From the Chronic Renal Insufficiency Cohort Study. <i>JAMA Cardiology</i> , 2016 , 1, 548-56	16.2	63
172	Tubular markers are associated with decline in kidney function in proteinuric type 2 diabetic patients. <i>Diabetes Research and Clinical Practice</i> , 2012 , 97, 71-6	7.4	62
171	Phosphate homeostasis in CKD: report of a scientific symposium sponsored by the National Kidney Foundation. <i>American Journal of Kidney Diseases</i> , 2013 , 62, 457-73	7.4	60
170	Fibroblast growth factor 23 in patients undergoing peritoneal dialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011 , 6, 2688-95	6.9	59
169	FGF-23 levels in patients with AKI and risk of adverse outcomes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012 , 7, 1217-23	6.9	58
168	Fibroblast Growth Factor 23 and Cause-Specific Mortality in the General Population: The Northern Manhattan Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016 , 101, 3779-3786	5.6	58
167	Fibroblast Growth Factor 23 Levels Associate with AKI and Death in Critical Illness. <i>Journal of the American Society of Nephrology: JASN</i> , 2017 , 28, 1877-1885	12.7	57
166	Vitamin D deficiency, inflammation, and albuminuria in chronic kidney disease: complex interactions. <i>Journal of Renal Nutrition</i> , 2011 , 21, 295-302	3	56
165	Dysregulated mineral metabolism in patients with acute kidney injury and risk of adverse outcomes. <i>Clinical Endocrinology</i> , 2013 , 79, 491-8	3.4	55
164	Fibroblast growth factor 23 levels are elevated and associated with severe acute kidney injury and death following cardiac surgery. <i>Kidney International</i> , 2016 , 89, 939-48	9.9	54
163	Atrial Fibrillation and Risk of ESRD in Adults with CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016 , 11, 1189-96	6.9	50
162	Persistent high serum bicarbonate and the risk of heart failure in patients with chronic kidney disease (CKD): A report from the Chronic Renal Insufficiency Cohort (CRIC) study. <i>Journal of the American Heart Association</i> , 2015 , 4,	6	49
161	Plasma FGF23 and the risk of stroke: the Northern Manhattan Study (NOMAS). <i>Neurology</i> , 2014 , 82, 1700-6	6.6	49
160	Food Access, Chronic Kidney Disease, and Hypertension in the U.S. <i>American Journal of Preventive Medicine</i> , 2015 , 49, 912-20	6.1	48
159	Risk Factors for Heart Failure in Patients With Chronic Kidney Disease: The CRIC (Chronic Renal Insufficiency Cohort) Study. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	47
158	Differential risk of hypertensive disorders of pregnancy among Hispanic women. <i>Journal of the American Society of Nephrology: JASN</i> , 2004 , 15, 1330-8	12.7	46
157	Klotho variants and chronic hemodialysis mortality. <i>Journal of Bone and Mineral Research</i> , 2009 , 24, 1847-55	6.5	45
156	Earlier onset and greater severity of disordered mineral metabolism in diabetic patients with chronic kidney disease. <i>Diabetes Care</i> , 2012 , 35, 994-1001	14.6	45

155	Use of Measures of Inflammation and Kidney Function for Prediction of Atherosclerotic Vascular Disease Events and Death in Patients With CKD: Findings From the CRIC Study. <i>American Journal of Kidney Diseases</i> , 2019 , 73, 344-353	7.4	42
154	Serum Calcification Propensity and Coronary Artery Calcification Among Patients With CKD: The CRIC (Chronic Renal Insufficiency Cohort) Study. <i>American Journal of Kidney Diseases</i> , 2019 , 73, 806-814	7.4	40
153	Daily variability in mineral metabolites in CKD and effects of dietary calcium and calcitriol. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012 , 7, 820-8	6.9	40
152	Insulin resistance but not inflammation is associated with gestational hypertension. <i>Hypertension</i> , 2002 , 40, 886-91	8.5	40
151	DMP1 prevents osteocyte alterations, FGF23 elevation and left ventricular hypertrophy in mice with chronic kidney disease. <i>Bone Research</i> , 2019 , 7, 12	13.3	39
150	Higher net acid excretion is associated with a lower risk of kidney disease progression in patients with diabetes. <i>Kidney International</i> , 2017 , 91, 204-215	9.9	38
149	A Pilot Randomized Trial of Ferric Citrate Coordination Complex for the Treatment of Advanced CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2019 , 30, 1495-1504	12.7	38
148	Fibroblast Growth Factor 23 and Anemia in the Chronic Renal Insufficiency Cohort Study. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017 , 12, 1795-1803	6.9	38
147	Correlates of osteoprotegerin and association with aortic pulse wave velocity in patients with chronic kidney disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011 , 6, 2612-9	6.9	38
146	Genetic Variants Associated with Circulating Parathyroid Hormone. <i>Journal of the American Society of Nephrology: JASN</i> , 2017 , 28, 1553-1565	12.7	37
145	Vitamin D in patients with renal failure: a summary of observational mortality studies and steps moving forward. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2007 , 103, 487-90	5.1	37
144	FGF23 modifies the relationship between vitamin D and cardiac remodeling. <i>Circulation: Heart Failure</i> , 2013 , 6, 817-24	7.6	36
143	Fibroblast growth factor 23 and the future of phosphorus management. <i>Current Opinion in Nephrology and Hypertension</i> , 2009 , 18, 463-8	3.5	36
142	Targeting Vascular Calcification in Chronic Kidney Disease. <i>JACC Basic To Translational Science</i> , 2020 , 5, 398-412	8.7	35
141	Regulation and Effects of FGF23 in Chronic Kidney Disease. <i>Annual Review of Physiology</i> , 2020 , 82, 365-390	9.1	35
140	Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial. <i>Nephrology Dialysis Transplantation</i> , 2021 , 36, 111-120	4.3	35
139	Fibroblast growth factor 23, high-sensitivity cardiac troponin, and left ventricular hypertrophy in CKD. <i>American Journal of Kidney Diseases</i> , 2013 , 61, 67-73	7.4	34
138	Racial differences in postprandial mineral ion handling in health and in chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2010 , 25, 3970-7	4.3	34

137	N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations in hemodialysis patients: prognostic value of baseline and follow-up measurements. <i>Clinical Chemistry</i> , 2008 , 54, 1339-48	5.5	34
136	Statistical Methods for Cohort Studies of CKD: Survival Analysis in the Setting of Competing Risks. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017 , 12, 1181-1189	6.9	33
135	Fibroblast Growth Factor 23 Associates with Death in Critically Ill Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018 , 13, 531-541	6.9	33
134	Dietary phosphorus restriction in advanced chronic kidney disease: merits, challenges, and emerging strategies. <i>Seminars in Dialysis</i> , 2010 , 23, 401-6	2.5	33
133	Diuretics, calciuria and secondary hyperparathyroidism in the Chronic Renal Insufficiency Cohort. <i>Nephrology Dialysis Transplantation</i> , 2011 , 26, 1258-65	4.3	32
132	Impact of poverty on serum phosphate concentrations in the Third National Health and Nutrition Examination Survey. <i>Journal of Renal Nutrition</i> , 2011 , 21, 140-8	3	30
131	Early pregnancy insulin resistance and subsequent gestational diabetes mellitus. <i>Diabetes Care</i> , 2005 , 28, 1207-8	14.6	30
130	Ferric citrate reduces fibroblast growth factor 23 levels and improves renal and cardiac function in a mouse model of chronic kidney disease. <i>Kidney International</i> , 2019 , 96, 1346-1358	9.9	29
129	(1-34) Parathyroid hormone infusion acutely lowers fibroblast growth factor 23 concentrations in adult volunteers. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012 , 7, 139-45	6.9	28
128	Fibroblast Growth Factor 23 Is Associated With Carotid Plaque Presence and Area: The Northern Manhattan Study. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015 , 35, 2048-53	9.4	27
127	Urban foodscape trends: Disparities in healthy food access in Chicago, 2007-2014. <i>Health and Place</i> , 2018 , 52, 231-239	4.6	27
126	Klotho, an antiaging molecule, attenuates oxidant-induced alveolar epithelial cell mtDNA damage and apoptosis. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2017 , 313, L16-L26 ^{5,8}	5.8	26
125	The Association Between Conversion to In-centre Nocturnal Hemodialysis and Left Ventricular Mass Regression in Patients With End-Stage Renal Disease. <i>Canadian Journal of Cardiology</i> , 2016 , 32, 369-77	3.8	25
124	Phosphate: a novel cardiovascular risk factor. <i>European Heart Journal</i> , 2013 , 34, 1099-101	9.5	25
123	Elevated FGF-23 in a patient with rhabdomyolysis-induced acute kidney injury. <i>Nephrology Dialysis Transplantation</i> , 2010 , 25, 1335-7	4.3	25
122	Recent advances in the rapidly evolving field of fibroblast growth factor 23 in chronic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2010 , 19, 335-42	3.5	25
121	Clinical research career development: the individual perspective. <i>Academic Medicine</i> , 2002 , 77, 1084-8	3.9	25
120	Examination of Potential Modifiers of the Association of APOL1 Alleles with CKD Progression. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015 , 10, 2128-35	6.9	24

119	FGF23 (Fibroblast Growth Factor-23) and Incident Hypertension in Young and Middle-Aged Adults: The CARDIA Study. <i>Hypertension</i> , 2018 , 72, 70-76	8.5	23
118	FGF23 and Nutritional Metabolism. <i>Annual Review of Nutrition</i> , 2017 , 37, 247-268	9.9	23
117	Race, Genetic Ancestry, and Estimating Kidney Function in CKD. <i>New England Journal of Medicine</i> , 2021 , 385, 1750-1760	59.2	23
116	Genetic background influences cardiac phenotype in murine chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2018 , 33, 1129-1137	4.3	22
115	Fibroblast Growth Factor 23 Is Associated With Subclinical Cerebrovascular Damage: The Northern Manhattan Study. <i>Stroke</i> , 2016 , 47, 923-8	6.7	22
114	Expression of fgf23 and β 10tho in developing embryonic tissues and adult kidney of the zebrafish, <i>Danio rerio</i> . <i>Nephrology Dialysis Transplantation</i> , 2012 , 27, 4314-22	4.3	22
113	Mineral (Mal)Adaptation to Kidney Disease--Young Investigator Award Address: American Society of Nephrology Kidney Week 2014. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015 , 10, 1875-85	6.9	21
112	Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside-a systematic review and meta-analysis. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 2256-2273	3.8	21
111	Beyond minerals and parathyroid hormone: role of active vitamin D in end-stage renal disease. <i>Seminars in Dialysis</i> , 2005 , 18, 302-6	2.5	20
110	A Randomized Trial Comparing the Safety, Adherence, and Pharmacodynamics Profiles of Two Doses of Sodium Bicarbonate in CKD: the BASE Pilot Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2020 , 31, 161-174	12.7	20
109	Associations of dietary phosphorus intake, urinary phosphate excretion, and fibroblast growth factor 23 with vascular stiffness in chronic kidney disease. <i>Journal of Renal Nutrition</i> , 2013 , 23, 12-20	3	19
108	Associations of socioeconomic status and processed food intake with serum phosphorus concentration in community-living adults: the Multi-Ethnic Study of Atherosclerosis (MESA). <i>Journal of Renal Nutrition</i> , 2012 , 22, 480-9	3	19
107	The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia. <i>Nephrology Dialysis Transplantation</i> , 2019 , 34, 339-346	4.3	19
106	Genetic Variants Associated with Circulating Fibroblast Growth Factor 23. <i>Journal of the American Society of Nephrology: JASN</i> , 2018 , 29, 2583-2592	12.7	19
105	Tertiary excess of fibroblast growth factor 23 and hypophosphatemia following kidney transplantation. <i>Pediatric Transplantation</i> , 2011 , 15, 37-46	1.8	18
104	Longitudinal Evolution of Markers of Mineral Metabolism in Patients With CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study. <i>American Journal of Kidney Diseases</i> , 2020 , 75, 235-244	7.4	18
103	Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference. <i>Kidney International</i> , 2021 , 99, 1280-1295	9.9	18
102	Race/Ethnicity and Cardiovascular Outcomes in Adults With CKD: Findings From the CRIC (Chronic Renal Insufficiency Cohort) and Hispanic CRIC Studies. <i>American Journal of Kidney Diseases</i> , 2016 , 68, 545-553	7.4	18

101	Association of serum phosphorus level with anemia in kidney transplant recipients. <i>Transplantation</i> , 2011 , 91, 875-82	1.8	17
100	Impact of westernization on fibroblast growth factor 23 levels among individuals of African ancestry. <i>Nephrology Dialysis Transplantation</i> , 2015 , 30, 630-5	4.3	16
99	A balanced view of calcium and phosphate homeostasis in chronic kidney disease. <i>Kidney International</i> , 2013 , 83, 789-91	9.9	16
98	Fibroblast growth factor 23 and incident CKD in type 2 diabetes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015 , 10, 29-38	6.9	16
97	Integrating research training into residency: tools of human investigation. <i>Academic Medicine</i> , 2009 , 84, 1295-300	3.9	16
96	Vitamin D and Health Outcomes: Then Came the Randomized Clinical Trials. <i>JAMA - Journal of the American Medical Association</i> , 2019 , 322, 1866-1868	27.4	15
95	Fibroblast Growth Factor-23 (FGF-23) Levels Differ Across Populations by Degree of Industrialization. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016 , 101, 2246-53	5.6	15
94	Acid Load and Phosphorus Homeostasis in CKD. <i>American Journal of Kidney Diseases</i> , 2017 , 70, 541-550	7.4	14
93	Randomised clinical trial of ferric citrate hydrate on anaemia management in haemodialysis patients with hyperphosphataemia: ASTRIO study. <i>Scientific Reports</i> , 2019 , 9, 8877	4.9	13
92	Diagnosis and management of mineral metabolism in CKD. <i>Journal of General Internal Medicine</i> , 2010 , 25, 710-6	4	13
91	Klotho: FGF23 coreceptor and FGF23-regulating hormone. <i>Journal of Clinical Investigation</i> , 2012 , 122, 4336-9	15.9	13
90	Cord Blood Ferritin and Fibroblast Growth Factor-23 Levels in Neonates. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016 , 101, 1673-9	5.6	13
89	Kidney Functional Magnetic Resonance Imaging and Change in eGFR in Individuals with CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020 , 15, 776-783	6.9	12
88	Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis. <i>CKJ: Clinical Kidney Journal</i> , 2020 , 13, 75-84	4.5	12
87	Pulmonary Hypertension Subtypes and Mortality in CKD. <i>American Journal of Kidney Diseases</i> , 2020 , 75, 713-724	7.4	12
86	Prognostic value of bone- and vascular-derived molecular biomarkers in hemodialysis and renal transplant patients: a systematic review and meta-analysis. <i>Nephrology Dialysis Transplantation</i> , 2017 , 32, 1566-1578	4.3	12
85	Genetic African Ancestry and Markers of Mineral Metabolism in CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016 , 11, 653-62	6.9	11
84	Fibroblast Growth Factor 23 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017 , 12, 1461-1469	6.9	11

83	Randomized evaluation of efficacy and safety of ferric carboxymaltose in patients with iron deficiency anaemia and impaired renal function (REPAIR-IDA): rationale and study design. <i>Nephrology Dialysis Transplantation</i> , 2010 , 25, 2368-75	4.3	11
82	Clinical problem-solving. Needle in a haystack. <i>New England Journal of Medicine</i> , 2006 , 354, 68-73	59.2	11
81	Novel Risk Factors for Progression of Diabetic and Nondiabetic CKD: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study. <i>American Journal of Kidney Diseases</i> , 2021 , 77, 56-73.e1	7.4	11
80	Single Measurements of Carboxy-Terminal Fibroblast Growth Factor 23 and Clinical Risk Prediction of Adverse Outcomes in CKD. <i>American Journal of Kidney Diseases</i> , 2019 , 74, 771-781	7.4	10
79	Fibroblast Growth Factor 23 Trajectories in Chronic Hemodialysis Patients: Lessons from the HEMO Study. <i>American Journal of Nephrology</i> , 2019 , 49, 263-270	4.6	10
78	Mechanism of action of SNF472, a novel calcification inhibitor to treat vascular calcification and calciphylaxis. <i>British Journal of Pharmacology</i> , 2020 , 177, 4400-4415	8.6	10
77	Creatinine versus cystatin C for renal function-based mortality prediction in an elderly cohort: The Northern Manhattan Study. <i>PLoS ONE</i> , 2020 , 15, e0226509	3.7	10
76	Fibroblast Growth Factor-23, Heart Failure Risk, and Renin-Angiotensin-Aldosterone-System Blockade in Hypertension: The MESA Study. <i>American Journal of Hypertension</i> , 2019 , 32, 18-25	2.3	10
75	Creatinine- versus cystatin C-based renal function assessment in the Northern Manhattan Study. <i>PLoS ONE</i> , 2018 , 13, e0206839	3.7	10
74	Serum levels of fibroblast growth factor 23 are elevated in patients with active Lupus nephritis. <i>Cytokine</i> , 2017 , 91, 124-127	4	9
73	Phosphate, fibroblast growth factor 23 and retinopathy in chronic kidney disease: the Chronic Renal Insufficiency Cohort Study. <i>Nephrology Dialysis Transplantation</i> , 2015 , 30, 1534-41	4.3	9
72	Vitamin D Metabolic Ratio and Risks of Death and CKD Progression. <i>Kidney International Reports</i> , 2019 , 4, 1598-1607	4.1	9
71	Biomarkers of Mineral and Bone Metabolism and 20-Year Risk of Hospitalization With Infection: The Atherosclerosis Risk in Communities Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 4648-4657	5.6	9
70	Increasing use of vitamin D supplementation in the chronic renal insufficiency cohort study. <i>Journal of Renal Nutrition</i> , 2014 , 24, 186-93	3	9
69	Multicenter Study Evaluating Intrarenal Oxygenation and Fibrosis Using Magnetic Resonance Imaging in Individuals With Advanced CKD. <i>Kidney International Reports</i> , 2018 , 3, 1467-1472	4.1	9
68	Fibroblast growth factor23 is associated with axonal integrity and neural network architecture in the human frontal lobes. <i>PLoS ONE</i> , 2018 , 13, e0203460	3.7	9
67	FGFR4 does not contribute to progression of chronic kidney disease. <i>Scientific Reports</i> , 2019 , 9, 14023	4.9	8
66	When there will never be a randomized controlled trial. <i>Kidney International</i> , 2015 , 88, 220-2	9.9	8

65	Nephrogenic systemic fibrosis is associated with hypophosphataemia: a case-control study. <i>Rheumatology</i> , 2014 , 53, 1613-7	3.9	8
64	Association of serum calcitonin with coronary artery disease in individuals with and without chronic kidney disease. <i>International Urology and Nephrology</i> , 2012 , 44, 1169-75	2.3	8
63	Health Behaviors in Younger and Older Adults With CKD: Results From the CRIC Study. <i>Kidney International Reports</i> , 2019 , 4, 80-93	4.1	8
62	Asymptomatic Ventricular Arrhythmia and Clinical Outcomes in Chronic Kidney Disease: A Pilot Study. <i>CardioRenal Medicine</i> , 2016 , 7, 66-73	2.8	7
61	Dietary factors and fibroblast growth factor-23 levels in young adults with African ancestry. <i>Journal of Bone and Mineral Metabolism</i> , 2017 , 35, 666-674	2.9	7
60	Fibroblast Growth Factor 23 and Risk of Hospitalization with Infection in Chronic Kidney Disease: The Chronic Renal Insufficiency Cohort (CRIC) Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2020 , 31, 1836-1846	12.7	7
59	Active vitamin D and survival. <i>Journal of the American Society of Nephrology: JASN</i> , 2008 , 19, 1442-3	12.7	7
58	Serial Fibroblast Growth Factor 23 Measurements and Risk of Requirement for Kidney Replacement Therapy: The CRIC (Chronic Renal Insufficiency Cohort) Study. <i>American Journal of Kidney Diseases</i> , 2020 , 75, 908-918	7.4	7
57	Intravenous Iron-Induced Hypophosphatemia: An Emerging Syndrome. <i>Advances in Therapy</i> , 2021 , 38, 3531-3549	4.1	7
56	Design and Rationale of HiLo: A Pragmatic, Randomized Trial of Phosphate Management for Patients Receiving Maintenance Hemodialysis. <i>American Journal of Kidney Diseases</i> , 2021 , 77, 920-930.e7	7.4	7
55	Racial/Ethnic Differences in Left Ventricular Structure and Function in Chronic Kidney Disease: The Chronic Renal Insufficiency Cohort. <i>American Journal of Hypertension</i> , 2017 , 30, 822-829	2.3	6
54	Modifiers of Plasma 25-Hydroxyvitamin D and Chronic Kidney Disease Outcomes in Black Americans: The Jackson Heart Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 , 104, 2267-2276	5.6	6
53	Safety of ferric derisomaltose and iron sucrose in patients with iron deficiency anemia: The FERWON-IDA/NEPHRO trials. <i>American Journal of Hematology</i> , 2021 , 96, E11-E15	7.1	6
52	Oral Ferric Citrate Hydrate Associated With Less Oxidative Stress Than Intravenous Saccharated Ferric Oxide. <i>Kidney International Reports</i> , 2018 , 3, 364-373	4.1	5
51	GFR-Specific versus GFR-Agnostic Cutoffs for Parathyroid Hormone and Fibroblast Growth Factor-23 in Advanced Chronic Kidney Disease. <i>American Journal of Nephrology</i> , 2019 , 50, 105-114	4.6	5
50	A physiologic-based approach to the evaluation of a patient with hyperphosphatemia. <i>American Journal of Kidney Diseases</i> , 2013 , 61, 330-6	7.4	5
49	Case records of the Massachusetts General Hospital. Case 28-2005. A 42-year-old man with weight loss, weakness, and a rash. <i>New England Journal of Medicine</i> , 2005 , 353, 1148-57	59.2	5
48	Change in Cardiac Biomarkers and Risk of Incident Heart Failure and Atrial Fibrillation in CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study. <i>American Journal of Kidney Diseases</i> , 2021 , 77, 907-919	7.4	5

47	Metabolic Changes with Base-Loading in CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018 , 13, 1244-1246	6.9	5
46	Anemia and Incident End-Stage Kidney Disease. <i>Kidney360</i> , 2020 , 1, 623-630	1.8	4
45	Mineral bone disease in autosomal dominant polycystic kidney disease. <i>Kidney International</i> , 2021 , 99, 977-985	9.9	4
44	Chicago supermarket data and food access analytics in census tract shapefiles for 2007-2014. <i>Data in Brief</i> , 2018 , 21, 2482-2488	1.2	4
43	Hypophosphatemia after intravenous iron therapy: Comprehensive review of clinical findings and recommendations for management. <i>Bone</i> , 2022 , 154, 116202	4.7	4
42	Inflammatory Markers and Incidence of Hospitalization With Infection in Chronic Kidney Disease. <i>American Journal of Epidemiology</i> , 2020 , 189, 433-444	3.8	3
41	Designing, Conducting, Monitoring, and Analyzing Data from Pragmatic Randomized Clinical Trials: Proceedings from a Multi-stakeholder Think Tank Meeting. <i>Therapeutic Innovation and Regulatory Science</i> , 2020 , 54, 1477-1488	1.2	3
40	Nephropathic Cystinosis: A Distinct Form of CKD-Mineral and Bone Disorder that Provides Novel Insights into the Regulation of FGF23. <i>Journal of the American Society of Nephrology: JASN</i> , 2020 , 31, 2184-2192	12.7	3
39	Does a rise in plasma erythropoietin after high-altitude exposure affect FGF23 in healthy volunteers on a normal or low-phosphorus diet?. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2019 , 29, 1361-1367	4.5	3
38	Phosphate Metabolism and Fibroblast Growth Factor 23 in Chronic Kidney Disease 2013 , 285-308		3
37	Differential effects of vitamin d receptor agonists on gene expression in neonatal rat cardiomyocytes. <i>Cardiovascular Drugs and Therapy</i> , 2011 , 25, 215-22	3.9	3
36	Racial Differences in the Associations Between Food Insecurity and Fibroblast Growth Factor 23 in the Coronary Artery Risk Development in Young Adults Study. <i>Journal of Renal Nutrition</i> , 2020 , 30, 509-517	5.1	3
35	Effects of ferric carboxymaltose on markers of mineral and bone metabolism: A single-center prospective observational study of women with iron deficiency. <i>Bone</i> , 2020 , 141, 115559	4.7	3
34	Lipocalin 2 stimulates bone fibroblast growth factor 23 production in chronic kidney disease. <i>Bone Research</i> , 2021 , 9, 35	13.3	3
33	Fibroblast Growth Factor 23 and Incident Cardiovascular Disease and Mortality in Middle-Aged Adults. <i>Journal of the American Heart Association</i> , 2021 , 10, e020196	6	3
32	Should activated vitamin D be used in patients with end-stage renal disease and low levels of parathyroid hormone?. <i>Seminars in Dialysis</i> , 2011 , 24, 428-30	2.5	2
31	Drug Development in Kidney Disease: Proceedings From a Multistakeholder Conference. <i>American Journal of Kidney Diseases</i> , 2020 , 76, 842-850	7.4	2
30	Association of circulating cardiac biomarkers with electrocardiographic abnormalities in chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2021 , 36, 2282-2289	4.3	2

29	Association between patient race and staff resuscitation efforts after cardiac arrest in outpatient dialysis clinics: A study from the CARES surveillance group. <i>Resuscitation</i> , 2020 , 156, 42-50	4	2
28	Fibroblast Growth Factor 23 and Exercise Capacity in Heart Failure with Preserved Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2021 , 27, 309-317	3.3	2
27	Predictors of Net Acid Excretion in the Chronic Renal Insufficiency Cohort (CRIC) Study. <i>American Journal of Kidney Diseases</i> , 2019 , 74, 203-212	7.4	1
26	Echocardiography to Screen for Pulmonary Hypertension in CKD. <i>Kidney International Reports</i> , 2020 , 5, 2275-2283	4.1	1
25	Sleep disordered breathing and fibroblast growth factor 23 in the Hispanic Community Health Study/Study of Latinos. <i>Bone</i> , 2018 , 114, 278-284	4.7	1
24	Kidney to bone via bedside to bench and back?. <i>Journal of Clinical Investigation</i> , 2020 , 130, 1106-1108	15.9	1
23	Pruning the ricket thicket. <i>Journal of Clinical Investigation</i> , 2016 , 126, 473-6	15.9	1
22	Persistent Hypophosphatemia after Ferric Carboxymaltose Is Associated with Persistent Changes in Biomarkers of Bone Metabolism. <i>Blood</i> , 2020 , 136, 13-14	2.2	1
21	Fibroblast Growth Factor-23 and Subclinical Markers of Cardiac Dysfunction: The Coronary Artery Risk Development in Young Adults (CARDIA) Study. <i>American Heart Journal</i> , 2021 , 245, 10-10	4.9	1
20	Fibroblast Growth Factor-23 and a Vegetarian Diet. <i>Journal of Renal Nutrition</i> , 2020 , 30, 503-508	3	1
19	Iron status, fibroblast growth factor 23 and cardiovascular and kidney outcomes in chronic kidney disease. <i>Kidney International</i> , 2021 , 100, 1292-1302	9.9	1
18	Statins at Dialysis Transition-Supportive but Not Sufficient. <i>JAMA Network Open</i> , 2018 , 1, e182411	10.4	1
17	Association of Fitness With Racial Differences in Chronic Kidney Disease. <i>American Journal of Preventive Medicine</i> , 2019 , 57, 68-76	6.1	0
16	Interactions between FGF23 and Genotype in Autosomal Dominant Polycystic Kidney Disease. <i>Kidney360</i> , 2020 , 1, 648-656	1.8	0
15	Abnormalities in Cardiac Structure and Function among Individuals with CKD: The COMBINE Trial.. <i>Kidney360</i> , 2022 , 3, 258-268	1.8	0
14	The Nephrology Immersion Classroom for Internal Medicine Residents.. <i>Kidney360</i> , 2020 , 1, 1060-1067	1.8	0
13	International Society of Nephrology Global Kidney Health Atlas: structures, organization, and services for the management of kidney failure in North America and the Caribbean. <i>Kidney International Supplements</i> , 2021 , 11, e66-e76	6.3	0
12	A Comparative Study of Serum Phosphate and Related Parameters in Chronic Kidney Disease between the USA and Japan.. <i>American Journal of Nephrology</i> , 2022 , 1-14	4.6	0

- 11 The Authors Reply. *Kidney International*, **2017**, 91, 1518-1519 9.9
- 10 Health Outcomes With Vitamin D Supplementation-Reply. *JAMA - Journal of the American Medical Association*, **2020**, 323, 1619 27.4
- 9 A Patient With CKD Develops Cholestatic Liver Injury During a Clinical Trial. *Kidney International Reports*, **2018**, 3, 5-10 4.1
- 8 Chronic kidney disease in patients with cognitive impairment: a marker of microvascular damage or an independent risk factor?. *Aging Health*, **2010**, 6, 423-427
- 7 Noninvasive Risk Score to Screen for Pulmonary Hypertension With Elevated Pulmonary Vascular Resistance in Diseases of Chronic Volume Overload. *American Journal of Cardiology*, **2021**, 159, 113-120 ³
- 6 Creatinine versus cystatin C for renal function-based mortality prediction in an elderly cohort: The Northern Manhattan Study **2020**, 15, e0226509
- 5 Creatinine versus cystatin C for renal function-based mortality prediction in an elderly cohort: The Northern Manhattan Study **2020**, 15, e0226509
- 4 Creatinine versus cystatin C for renal function-based mortality prediction in an elderly cohort: The Northern Manhattan Study **2020**, 15, e0226509
- 3 Creatinine versus cystatin C for renal function-based mortality prediction in an elderly cohort: The Northern Manhattan Study **2020**, 15, e0226509
- 2 Creatinine versus cystatin C for renal function-based mortality prediction in an elderly cohort: The Northern Manhattan Study **2020**, 15, e0226509
- 1 Creatinine versus cystatin C for renal function-based mortality prediction in an elderly cohort: The Northern Manhattan Study **2020**, 15, e0226509